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OPINION Open Access
What can we offer to 3 million MDRTB
household contacts in 2016?
David A. J. Moore
Abstract
The diagnosis of multidrug resistant tuberculosis (MDR-TB) in any individual is the beginning of a prolonged and
difficult therapeutic journey. It also marks the moment from which to begin consideration of how to manage close
contacts. Preventive therapy for drug-susceptible latent tuberculosis infection has been demonstrated to be
effective at reducing the risk of future disease; the stakes are higher when considering prevention of MDR-TB
because treatment of active disease is more prolonged and toxic and much less effective. This has encouraged
exploration of the potential utility of preventive therapy, with second-line agents, in reducing future incident
drug-resistant TB.
Three clinical trials of preventive therapy for contacts of patients with MDR-TB are starting in 2015/16; results will
not be available until at least 2020, so what should be offered to exposed contacts in the interim?
A recent policy brief, arising from a global consultation meeting of international experts, recommended preventive
therapy based upon very limited available observational data. However the many known unknowns associated with
this approach, include the high proportion of index-contact pairs with discordant drug susceptibility profiles and
(even if susceptibilities are shared) the lack of data supporting the use of the selected agents in the treatment of
latent infection (rather than active disease).
It is important to acknowledge that the alternative to offering preventive therapy is not doing nothing. On the
contrary, identified contacts should be maintained under close, active surveillance for 24 months, enabling early
detection of active disease in the small proportion amongst whom this may occur. Such patients should benefit
from less extensive disease at diagnosis and early access to individualized therapeutic regimens with improved
treatment outcomes. Moreover the vast majority of contacts that do not develop disease will benefit from
avoidance of potentially toxic, unnecessary therapy.
Whether preventive therapy or close observation are implemented, national programmes should maintain a register
of all contacts, interventions and 24 month outcomes; these will provide important performance metrics for
programmatic management of MDRTB. If harmonized and standardized internationally, such a register could rapidly
yield a wealth of observational data, to complement the trial results of the future.
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MDRTB in 2015
Multidrug resistant tuberculosis (MDRTB) is defined as
TB resistant to isoniazid and rifampicin. The World
Health Organisation estimated that there were around
480,000 incident cases of MDRTB in 2014 [1]. In con-
trast to TB susceptible to these agents, which is effect-
ively treated with a six-month course of generally well
tolerated chemotherapy, current recommendations for
MDRTB require treatment for a minimum of 20 months
with a combination that includes a daily injectable agent
for at least the first eight months [2]. Such regimens are
highly toxic and poorly tolerated with the additional
sting of poor efficacy. Globally only 50 % of MDRTB pa-
tients achieve a successful treatment outcome (cure or
completion of treatment) [1]. Many of the 190,000
people estimated to have succumbed to MDRTB in 2014
died even before a diagnosis could be made. There is
much work to be done to increase MDRTB detection, to
enhance linkage of diagnosis to initiation of appropriate
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treatment, and to improve efficacy and tolerability of
MDRTB therapy. However there is cause for optimism.
Scale-up of diagnostics for MDRTB continues, even if
the goal of universal drug susceptibility testing (DST)
still seems a distant, unaffordable aspiration, and new
regimens [3] and agents [4, 5] for MDRTB therapy hold
the promise that shorter, exclusively oral regimens may
become the standard of care within a few years.
The elephant in the room
That many more patients are being diagnosed with
MDRTB each year is a good thing, representing much
improved case ascertainment rather than necessarily a
growing problem (though both may be true). Patients
are more likely to receive appropriate therapy, reducing
morbidity and mortality at the individual level and inter-
rupting transmission earlier at the population level.
However there is a responsibility that accompanies every
MDRTB diagnosis that is currently being shirked by
most national TB control programmes (NTPs), over-
whelmed as they often are by competing priorities, and
that is how to manage MDRTB-exposed household
contacts.
Here, we are in a data desert, and guidance on preven-
tion of MDRTB from the World Health Organisation is
not particularly illuminating (“(1) Early detection and
high quality treatment of drug susceptible TB, (2) early
detection and high quality treatment of drug resistant
TB, (3) effective implementation of infection control
measures, (4) strengthening and regulation of health sys-
tems, (5) addressing underlying risk factors and social
determinants” [2]).
As a minimum all household contacts should be identi-
fied and screened for active TB disease soon after index
case diagnosis, and rapid drug susceptibility testing should
be performed for all co-incident cases. The high yield of
active case finding within TB-affected households [6, 7] is
particularly valuable if additional drug-resistant cases can
be removed from the pool of infectious individuals sus-
taining transmission within the community. After identifi-
cation of co-incident household cases the next step is to
decide what, if anything, can be offered to the remaining
MDR-exposed household contacts to manage their risk of
future MDRTB.
What are the options?
Lessons from management of drug-susceptible latent
infection
It is worth considering what can be learnt from the ap-
proach taken when the index case has drug susceptible
disease. For close contacts of index cases known to have
drug-susceptible TB (susceptible to rifampicin and iso-
niazid) who are deemed to be at high risk of progression
to active disease – young children, HIV-infected,
immunosuppressed – preventive therapy with isoniazid
is recommended [8, 9]. There is strong evidence that this
affords good protection against subsequent TB disease
in well-defined populations [10]. In low incidence set-
tings where the force of infection is low this is presumed
to be mediated through sterilization of existing latent in-
fection preventing reactivation disease, whereas in high
burden settings waning efficacy after PT is discontinued
[11] suggests that there may also be an effect mediated
whilst taking therapy through prevention of the estab-
lishment of further infection on re-exposure [12].
Most studies demonstrate that PT efficacy is greatest
amongst subjects with a positive tuberculin skin test
(TST) [13], though this is not a universal finding [14],
Moreover the discourse about TST-negative subjects,
particularly amongst patients with HIV, fails to ad-
equately recognise that this group is a mix of those who
can correctly be assumed to not have LTBI and those
unable to mount a response to any antigen, not just tuber-
culin, by virtue of profound immunodeficiency and who
may therefore be at particularly high risk of reactivation of
unrecognised LTBI. Neither TST nor interferon-gamma
release assays (IGRAs) serve us well in deciding who is at
highest risk of future progression to active TB. Moreover
the need for such a gateway test has been a major impedi-
ment to the scale-up of isoniazid preventive therapy [15]
as part of the World Health organisations “3 I s” for tack-
ling HIV-associated TB. All of which is to say that in con-
sideration of how to manage MDRTB household contacts,
for whom the stakes may be somewhat higher, it should
not be assumed that decision making necessarily starts
with (flawed) testing for LTBI.
What then can be offered to MDRTB contacts?
An ideal preventive therapy regimen should include a sec-
ond line agent(s) which is (1) effective against non- or
slowly replicating organisms and (2) for which there is a
high likelihood that the infecting strain is susceptible. On
the first point it is noteworthy that had the mechanism of
action of isoniazid [16], a drug which only kills actively
growing mycobacteria, been understood at the time it is
doubtful it would ever have been proposed for preventive
therapy. Arguably therefore, whilst intuitively desirable,
this may not be an absolute requirement.
For the second point it comes down to probability, be-
cause there is currently no way to determine the drug
susceptibility of the LTBI strain. What is the likelihood
that the strain of an MDR contact with LTBI will have a
drug susceptibility test (DST) profile that is no more re-
sistant than that of the index case, and therefore poten-
tially treatable with an agent(s) selected on the basis of
index case DST? The only data we have is from studies of
second cases amongst household contacts. Whilst it might
be argued that these cases may not be representative of all
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MDR LTBI – drug resistance conferring mutations exact-
ing a “fitness cost” on some infecting strains [17, 18], re-
ducing their capacity for reactivation, and thus remaining
invisible – the strains of those second cases are neverthe-
less precisely those that should be targeted.
Studies examining DST concordance (genotypic or
phenotypic) between index MDRTB and subsequent in-
cident TB cases in the same household have been largely
conducted in high TB burden settings where the risk of
infection outside the household is also important. The
proportion of within-household second (rather than sec-
ondary) cases that do not share the index case DST
varies widely (in studies with >10 DST pairs tested,
concordance was 18, 60, 62, 72, 88 % [19]), indicating in-
fection was acquired elsewhere. Concordance is higher
amongst closer contacts who share the same bedroom
and contacts with HIV or diabetes and when the index
case is smear-positive [7] but beyond this there is little
data on characteristics of index case, contact, strain or
household environment that help to estimate the likeli-
hood that a contact will share the same strain.
Given the significantly lower efficacy and greater tox-
icity of second line agents used in the treatment of
MDRTB it is essential that immediate DST be performed
for all second cases to ensure the correct regimen is ini-
tiated. The implication for preventive therapy decision-
making is also clear: it is incorrect to assume that a
second line agent would be necessary for all MDRTB
contacts with LTBI needing preventive therapy. How-
ever, conversely whilst isoniazid would not be expected
to be effective in MDRTB LTBI, use of a second line
agent effective against latent MDRTB strains should
equally effectively sterilize non-MDR strains. Thus if the
selected second line agent were well tolerated, the
index-contact question becomes less about concordance
and more about the much lower probability that the
contact case harbours an LTBI strain which is more re-
sistant than the index case. Tailored preventive therapy,
selecting a drug by estimating the probability of strain
susceptibility would pose a major operational challenge
and since data on therapeutic efficacy will only be
available for a few agents within the next 5-10 years
such an approach would probably be better used to de-
termine whether success is likely for the few drugs
available.
What candidate agents may be suitable?
Several clinical trials of preventive therapy have been
scheduled to commence in 2015 and 2016 (Table 1);
protocol regimens and study populations have under-
standably evolved as observational evidence has grown
and new agents have become available. Levofloxacin is the
current poster-boy – available in a generic formulation,
once daily dosing and well tolerated by all age groups [20],
with good anti-mycobacterial activity against susceptible
strains. That one fifth of MDR strains tested in 2014 dem-
onstrated quinolone resistance [1] (albeit only represent-
ing one quarter of globally notified cases) raises cause for
concern about the long-term viability of use of this class
of drug, which is widely available over the counter in
many high TB burden countries. Interest in incorporating
delamanid, a new nitroimidazole [5], and one of two novel
anti-tuberculosis agents approved in recent years, into the
planned trials, highlights the reservations of investigators
about both the long term durability of quinolone utility
and biological plausibility about activity against non-
replicating organisms of agents that operate through inter-
ference with DNA gyrase [21].
Disappointingly there does not seem to be a current
appetite for a bolder, short duration option, such as has
recently been demonstrated for drug-susceptible LTBI in
which 12 doses of rifapentine plus isoniazid adminis-
tered once weekly over 3 months performs as well as
270 doses of daily isoniazid over 9 months [22].
However these trials ultimately finalise their interven-
tion designs it is to be hoped that there will be an attempt
at this early stage to harmonise subgroup eligibility criteria
and collection of core treatment outcome data so that on
completion all may contribute to a coherent body of evi-
dence. Questions around operational feasibility, such as
whether direct observation of therapy is needed or how to
respond if quinolone resistance is subsequently identified
in the index case, will also be key to understanding how to
translate the research findings into future policy and
practice.
Trials will not start reporting until at least 2020 so how
should MDRTB contacts be managed now?
This question was central to a meeting held in Dubai in
April 2015 (“Global Consultation on Best Practices in
the Delivery of Preventive Therapy for Households
Table 1 Randomised controlled trials of preventive therapy for MDRTB household contacts (HIV-infected or HIV-uninfected)
expected to commence recruitment in 2015
Name of trial Location Population Intervention and comparator Months of treatment/
follow-up
Clinical trials registry #
TB CHAMP South Africa Children <5 years Levofloxacin vs. placebo 6/18 -
PHOENix ACTG sites All contacts (Adults and children) Delamanid vs. isoniazid 6/22 -
V-QUIN Vietnam All contacts (Adults and children) Levofloxacin vs. placebo 6/30 ACTRN12616000215426
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Exposed to Drug-Resistant Tuberculosis”), from which a
policy brief was published in November 2015 [23].
Following review and discussion of published and un-
published data a set of seven guiding principles was laid
out: (1) define common terms, (2) identify all household
contacts, (3) evaluate all exposed individuals for TB dis-
ease, (4) offer treatment for MDRTB infection, (5) follow
all exposed individuals for at least 18 months, (6) build a
programmatic strategy to treat MDRTB infection, (7)
learn from the experiences in treating DS-TB infection.
The treatment recommended, based upon the majority
opinion of the gathered experts, was a fluoroquinolone
for at least 6 months either alone or in combination with
ethambutol or ethionamide (according to index case
DST profile). In total the observational data reports
upon 650 patients treated with a wide variety of regi-
mens, at least one third of whom received three agents
for six months and another third who received
pyrazinamide-containing regimens with high toxicity-
related discontinuation (thus pyrazinamide is not recom-
mended). The remaining 256 preventive therapy treated
patients thus represent the global experience upon
which the drug treatment recommendations are made,
on data from observational, often retrospective studies,
without adequate comparator control groups.
What alternatives to preventive therapy can be offered?
The presentation of recommendations [23] in the high-
quality-evidence vacuum is to be welcomed, particularly
when they are the considerations of a group representing
most of the global experience and interest in addressing
this issue. However the alternative to preventive therapy,
on which considerable emphasis is placed in the policy
brief, is not to do nothing at all. On the contrary, every
identified contact should be registered and actively
followed up for 2 years (the period of maximum risk) to
enable early detection of active TB disease and rapid ini-
tiation of appropriate DST-directed therapy.
Previously, the typical patient with MDRTB will have
endured months to years of ineffective treatment with a
clinical presentation characterised by significant systemic
illness (cachexia, anaemia), extensive lung damage with
sanctuary sites hard to reach with drug therapy, and high
mycobacterial bacillary burden. The adage that preven-
tion is better than cure would clearly apply in this situ-
ation – even a modestly effective preventive regimen
that could avert the drug toxicity, patient morbidity and
mortality, community-level transmission and health sys-
tem cost would be worthwhile.
However the growing availability of DST should drive
the “typical” patient towards a less advanced disease
phenotype at the onset of MDRTB therapy, which intui-
tively should translate into higher rates of treatment suc-
cess (even if data demonstrating this effect are so far
lacking (Harris RC, Allen V, Miller AJP, et al: A system-
atic review of the effect of early versus late treatment
initiation on the outcomes of patients treated for multi-
drug resistant tuberculosis, submitted)). Moreover pa-
tients identified within a few months of symptom onset
by virtue of close NTP surveillance may respond very
well to MDRTB treatment (with shorter duration of in-
fectiousness), including with the shorter regimens. This,
and the recognition that 90 % of contacts will never pro-
gress to active disease and thus would receive preventive
therapy unnecessarily, shifts the risk-benefit balance
back towards close contact surveillance rather than pre-
ventive therapy of unknown efficacy. This also plays into
the question of which contacts should be offered pre-
ventive therapy – people living with HIV, young chil-
dren, all contacts? The number needed to treat to
prevent a single case rapidly increases in the absence of
risk factors for progression.
Conclusions - what should national TB control
programmes be doing now?
For now, early diagnosis and treatment remains the key
to minimizing MDRTB morbidity and transmission. In
this regard the high yield of co-prevalent active disease
in household contacts and the high incidence of active
disease in the two years following index case diagnosis
are low-hanging fruit [19].
All household contacts should be identified and en-
tered into a national registry as an integral element of
the management of each patient treated for MDRTB. Fu-
ture MDRTB management might better be conceived as
household-centred rather than patient-centred care. The
level of sophistication required to deliver MDRTB treat-
ment includes IT capability into which an electronic
registry could readily be incorporated. Ideally an inter-
nationally agreed minimum dataset for such a registry
should be established and, with appropriate data protec-
tion safeguards, a curated internationally coordinated
database could be developed and offered to countries.
All contacts should then be followed-up for two years
from the date of index case diagnosis, whether offered
and/or receiving preventive therapy or not. The form of
follow up could include symptom screening, sputum
culture or Xpert MTB/RIF or radiology as decided locally
according to resource availability; contact frequency, even
if only for a quick symptom screen, should be at least
quarterly to maximise the chance of early diagnosis. All
investigations, diagnoses, therapies and outcomes could
be readily collected into the registry, which would rapidly
become both an auditable resource generating metrics by
which NTPs could evaluate their programmatic manage-
ment of drug resistant tuberculosis (PMDT) and a valu-
able source of detailed, systematically collected, unbiased
observational data. At an international level every MDRTB
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contact would thus contribute data to a rapidly enlarging
knowledge and evidence-base. Whilst awaiting the high
quality evidence from randomised trials we could at least
reassure ourselves that we were doing the very best that
we could for the 3 million-plus household contacts
around the globe who are asking “what about us?”.
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